17 Decemeber 2014

**Amarex Clinical Research Site Passes Surprise FDA Audit for a Multicenter, Randomized-Controlled Clinical Trial in Surgical Wound Healing and Cosmesis Study Submitted to FDA for Approval**

Germantown, MD, USA - A site taking part in an Amarex Clinical Research-supervised Surgical Wound Healing and Cosmesis study recently passed a surprise FDA audit with no findings. The audit was planned for 4 days but finished earlier than expected, and no FDA Warning Letter (Form 483) was issued.

Amarex CEO Dr. Kazem Kazempour said "this successful audit highlights the dedication and work ethic that Amarex's professionals are known for. The result of this audit speaks of Amarex's high standards of quality."

Amarex is a global Contract Research Organization (CRO) that provides complete clinical product development services to bioscience companies to achieve FDA approval for their new medical products. General Service categories include: 1) product development plan creation, 2) pre-clinical and clinical trial conduct, 3) applications to the FDA for marketing approval of new or improved medical products.

Contact:
Mirtha Lopez
mirthal@amarexcro.com
20201 Century Blvd, 4th Floor
Germantown, MD 20874
USA
+1-301-528-7000